[Biomarkers in renal cancer.]

Area of Science:

• Oncology
• Molecular Biology
• Urology

Background:

• Renal cell carcinoma (RCC) exhibits unpredictable behavior, with rising incidence despite advancements in understanding the disease.
• Significant mortality associated with kidney cancer underscores the urgent need for improved diagnostic and therapeutic strategies.
• Current research focuses on understanding molecular pathways to develop novel treatments for RCC.

Purpose of the Study:

• To review the main molecular markers studied in renal cell cancer.
• To evaluate the potential value of these markers in diagnosis, prognosis, and predicting treatment response.
• To highlight the importance of molecular pathway knowledge for developing new RCC therapies.

Main Methods:

• Literature review of published studies on renal cell cancer molecular markers.
• Analysis of current research on the role of molecular pathways in RCC.
• Synthesis of information on diagnostic, prognostic, and predictive biomarkers for kidney cancer.

Main Results:

• Molecular pathway knowledge has enabled reclassification of renal cell tumors.
• Several key molecular markers have been identified and studied for their potential in RCC.
• The search for reliable biomarkers remains a critical challenge for personalized medicine in kidney cancer.

Conclusions:

• Understanding molecular pathways is crucial for advancing renal cell cancer treatment.
• Biomarkers are essential for accurate diagnosis, prognosis, and tailoring therapies for kidney cancer patients.
• Continued research into molecular markers holds promise for improving outcomes in renal cell carcinoma.